Theradaptive

Company profile

Theradaptive company profile

Theradaptive is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, soft tissue repair and targeted immuno-oncology. The Company’s platform converts recombinant proteins into material-binding variants that can coat implants, devices and injectable carriers for vascular, soft tissue and orthopedic repair, enabling physicians to treat conditions that directly impact patients' lives. The company’s lead candidate, OsteoAdapt SP™, is an investigational biologic being evaluated in a Phase I/II clinical trial for patients with degenerative disc disease, a condition characterized by the deterioration of spinal joints that results in pain and dysfunction, and combines Theradaptive's next-generation engineered protein AMP2™, a modified, adhesive variant of the powerful bone-forming growth factor bone morphogenetic protein-2 (BMP-2), with a synthetic bone graft.